logo
More Sit-to-Stand Transitions Benefit Postmenopausal Women

More Sit-to-Stand Transitions Benefit Postmenopausal Women

Medscape5 days ago
TOPLINE:
Reducing sedentary behavior with interventions such as increasing daily sit-to-stand transitions might help lower blood pressure in postmenopausal women with overweight or obesity.
METHODOLOGY:
Researchers conducted a randomized controlled trial to assess how different strategies to reduce time spent sitting affected the physiologic responses of postmenopausal women who led sedentary lives.
The researchers included 407 women in the postmenopausal phase (mean age, 68 years; 92% White) who had overweight or obesity (average BMI, 32), had a sitting time of at least 7 hours a day, and performed no more than 70 sit-to-stand transitions daily.
The women were randomly assigned to one of three study arms: healthy living (n = 135), sit less (n = 136), and increased sit-to-stand transitions (n = 136). All arms received seven sessions of individual health coaching over 12 weeks.
Researchers assessed blood pressure and markers of glucose regulation using fasting blood samples. Readings from thigh- and hip-worn accelerometers for 7 days were used to evaluate posture, sedentary behavior, and physical activity.
Primary outcomes were measurements of glucose regulation and resting blood pressure at baseline and 3 months.
TAKEAWAY:
A total of 388 women completed the trial, with no serious adverse events related to the study.
Participants in the sit-less arm had a daily sitting time of approximately 58 minutes less than those in the healthy-living arm (P < .001), whereas those in the sit-to-stand arm had 26 more sit-to-stand transitions daily (P < .001).
Diastolic blood pressure fell by 2.24 mm Hg in the sit-to-stand arm compared with the healthy living arm (P = .02); the decrease in systolic blood pressure did not reach a predefined significance level.
Compared with the healthy-living arm, neither intervention produced significant changes in markers of glucose regulation.
IN PRACTICE:
'Postmenopausal women are at high risk of engaging in large amounts of sitting time and cardiovascular diseases. The present randomized controlled trial adds to existing evidence by demonstrating that within just 3 months, increasing' sit-to-stand transitions can lower diastolic blood pressure, the researchers wrote.
SOURCE:
This study was led by Sheri J. Hartman, PhD, University of California, San Diego. It was published online on July 25, 2025, in Circulation.
LIMITATIONS:
The generalizability of findings was limited by the lack of ethnic and racial diversity. The 3-month intervention period may have been too brief to observe sizeable physiologic changes. Measurement of only fasting glucose parameters could not capture changes after meals.
DISCLOSURES:
This study received support from the National Institute of Aging. Additional support was provided by the Altman Clinical & Translational Research Institute at the University of California, San Diego, funded by the National Center for Advancing Translational Sciences. The authors did not report any conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Novo Nordisk Stock Bumped Higher on Friday
Why Novo Nordisk Stock Bumped Higher on Friday

Yahoo

time22 minutes ago

  • Yahoo

Why Novo Nordisk Stock Bumped Higher on Friday

Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Bumped Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Addus HomeCare (ADUS) Q2 Earnings: What To Expect

Yahoo

time22 minutes ago

  • Yahoo

Addus HomeCare (ADUS) Q2 Earnings: What To Expect

Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

More than 9,000 Arlington ISD students receive free backpacks at back-to-school kickoff
More than 9,000 Arlington ISD students receive free backpacks at back-to-school kickoff

CBS News

time36 minutes ago

  • CBS News

More than 9,000 Arlington ISD students receive free backpacks at back-to-school kickoff

North Texas students can hit the snooze button for a few more mornings, but thousands of Arlington ISD families were up bright and early Saturday to prepare for the first day of school. Long lines of parents and students entered AT&T Stadium for the 11th annual Arlington ISD Back to School Kickoff. More than 9,000 students received backpacks filled with school supplies to help them start the school year on the right foot. In addition to backpacks, students received free haircuts, medical screenings and other services. The event aimed to ease the financial burden many families face at the start of the school year. "Being able to come and receive these backpacks filled with school supplies and get the health screenings is such a great blessing because a lot of things cost so much," said parent Patreece Dade. Xander Dade, a rising junior, said the backpack was packed with essentials. "It's heavy with certain surprises like binders, colored pencils, pencils, notebooks—things that I do need," he said. "Going into the new school year as a rising junior, we have the PSAT and important things that are coming up." The Gene and Jerry Jones Family Arlington Youth Foundation sponsored the event, which has provided more than 100,000 backpacks to students over the past 11 years. "Today was about ensuring that all of those resources are lined up so that we can take that load off of the student when they walk into our school buildings," said Arlington ISD Superintendent Dr. Matt Smith. "We want them to be able to focus on learning." Parents who missed the event and still need supplies can contact Arlington ISD's Family and Community Engagement department for assistance.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store